Compugen's Therapeutic Programs are focused in the fields of immunology and oncology, and consist of therapeutic candidates or targets that have been initially predicted in silico utilizing our proprietary discovery approach (es), and then successfully demonstrated functional activity in vitro and in vivo.

Compugen's Therapeutic Pipeline Program includes both Fc-Fusions for Autoimmune diseases (listed to the left), Monoclonal antibodies for Oncology
http://cgen.com/usa-activity   as well as earlier discoveries’ -peptide product candidates which were discovered during the discovery approach validation process.

 In 2010 we initiated our Pipeline Program pursuant to which we intend to both (i) substantially increase the number of predicted and selected product candidates being evaluated by us, and (ii) take selected product candidates further beyond their proof of concept into preclinical activities. 

Earlier discoveries include the following: CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway, which exhibited positive therapeutic effects in an animal model of retinopathy, including an additive effect in combination with a VEGF inhibitor, with potential therapeutic utility in cancer and inflammatory conditions; CGEN-25007, a novel peptide antagonist of gp96, which exhibited anti-inflammatory activity in vitro and in vivo in animal models of endotoxemia and inflammatory bowel disease (IBD), with potential therapeutic utility in autoimmune and inflammatory conditions; CGEN-25009, a novel peptide of the LGR7 receptor, which exhibited positive effect in vivo  in a mouse model of bleomycin-induced pulmonary fibrosis, with potential utility in fibrosis conditions such as pulmonary fibrosis and in heart failure; CGEN-855, is a novel peptide agonist of the FPRL1 GPCR receptor, which exhibited therapeutic potential in several animal models including acute inflammation, acute myocardial infarction (AMI) , and inflammatory bowel disease (IBD), with potential therapeutic utility in acute and chronic inflammation, as well as cardiovascular diseases; CGEN-856 & CGEN-857, novel ligands of the MAS GPCR receptor, which exhibited relaxation of rat and murine aorta, reduced in-vivo cardiac remodeling, and displayed anti-hypertensive effects as well as cardiac and renal anti-fibrotic effects, with potential utility in hypertension and cardiovascular pathologies; CGEN-25008, is a novel peptide that corresponds to a segment clusterin, which exhibited therapeutic effect in a xenograft animal model of lung cancer.